Dr. Chern, Yijuang 's publons link picture Dr. Chern, Yijuang 's Youtube

Dr. Chern, Yijuang

Director
Distinguished Research Fellow
  • +886227899028 (Lab) (Room No: N333)
  • +886226523913 (Office)
  • 02-27829143 (Fax)
Specialty:
  • Signal Transduction
  • Gene Regulation
  • Neurodegeneration Disease
Education and Positions:

  • Ph.D. Univ. of Massachusetts

We focus on two interrelated research projects: (1) functional characterization of the A2A adenosine receptor (A2AR) and (2) development of novel therapeutic treatment for degenerative diseases including Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease (AD).

     A2AR is a major target of caffeine, the most widely used psychoactive substance in the world. My laboratory started from the cloning of this receptor many years ago, and have extend our research interests into the regulation and signal transduction of A2AR under pathophysiological conditions, especially in neurodegenerative diseases. We have also set out to identify and delineate novel pathogeneses (e.g., Galectins-mediated neuroinflammation and abnormal GABAergic signaling) in diseased brains so that better treatments can be designed.

     In addition, we developed a group of adenosine analogues targeting simultaneously at A2AR and an adenosine transporter (ENT1). These compounds can enter the brain to enhance the adenosine tone, and can be used to treat mouse models of at least five protein aggregation diseases (including HD, ALS, SCA3, SCA7, AD, and Niemann-Pick type C disease). Results of our findings have led to the application and approvals of patents on applying these compounds to the development of therapeutic treatments for neurodegenerative diseases.

Our Team
Team photo

Journal 133 Book 4

  1. 1.Siew JJ, Chen H-M, Chiu F-L, Lee C-W, Chang Y-M, Chen H-L, Nguyen TNA, Liao H-T, Liu M, Hagar H-T, Sun Y-C, Lai H-L, Kuo M-H, Blum D, Buee L, Jin L-W, Chen S-Y, Ko T-M, Huang J-r, Kuo H-C, Liu F-T, Chern Y* Galectin-3 aggravates microglial activation and tau transmission in tauopathy. JOURNAL OF CLINICAL INVESTIGATION (2023-11-21) [JCR] [WOS]
  2. Ho S-Y, Chen I-C, Tsai C-W, Chang K-C, Lin C-J, Chern Y, Liou H-H* Anticonvulsant effect of equilibrative nucleoside transporters 1 inhibitor in a mouse model of Dravet syndrome. HIPPOCAMPUS 34(1), 7-13 (2023-11-06) [JCR] [WOS]
  3. Siew Jian Jing, Chern Yijuang, Khoo Kay-Hooi, Angata Takashi Roles of Siglecs in neurodegenerative diseases. Molecular Aspects of Medicine 90, 101141 (2023-04) [JCR] [WOS]
  4. Chen Ching-Ya, Chou Fang-Yi, Chang Ya-Gin, Ho Chin-Jui, Wu Kuo-Chen, Hsu Chia-Lin, Chern Yijuang, Lin Chun-Jung Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington\'s disease. Neurobiology of Disease 177, 106004 (2023-02) [JCR] [WOS]
  5. Chen Kuan-Yu, Lu Chiao-Shin, Pang Cheng-Yoong, Ho Chin-Jui, Wu Kuo-Chen, Yang Hsiu-Wei, Lai Hsin-Lin, Chern Yijuang, Lin Chun-Jung Equilibrative Nucleoside Transporter 1 is a Target to Modulate Neuroinflammation and Improve Functional Recovery in Mice with Spinal Cord Injury. Molecular Neurobiology 60(1), 369-381 (2023-01) [JCR] [WOS]
  6. Lee Yan Hua, Lee Yi‐Chung, Tsai Yu‐Shuen, Yang Ueng‐Cheng, Cheng Tzu‐Hao, Chern Yijuang, Soong Bing‐Wen Reply to: “Low Frequency of p.S510G in PIAS1 Challenges Its Relevance for Modifying Repeat Expansion Disorders”. Movement Disorders 37(10), 2169-2169 (2022-10-17) [JCR] [WOS]
  7. Yu-Ting Weng, Hui-Mei Chen, Ting Chien, Feng-Lan Chiu, Hung-Chih Kuo, (Yijuang Chern)* TRAX Provides Neuroprotection for Huntington\'s Disease Via Modulating a Novel Subset of MicroRNAs. Movement Disorders 37(10), 2008-2020 (2022-10-17) [JCR] [WOS]
  8. Wang Lee-Hsin, Lin Chien-Yu, Lin Yu-Mei, Buée Luc, Sergeant Nicolas, Blum David, Chern Yijuang, Wang Guey-Shin Calpain-2 Mediates MBNL2 Degradation and a Developmental RNA Processing Program in Neurodegeneration. The Journal of Neuroscience 42(25), 5102-5114 (2022-05-23) [JCR] [WOS]
  9. Peyton L, Leon B, Essa H, Chern Y, Choi DS N$^6$-Substituated Adenosine Analog J4 Attenuates Anxiety-like Behaviors in Mice. PSYCHOPHARMACOLOGY 239, 887-895 (2022-01-31) [JCR] [WOS]
  10. Yan Hua Lee, BSc, Yu-Shuen Tsai, Che-Chang Chang, Chun-Chen Ho, Hsiu-Ming Shih, Hui-Mei Chen, Hsing-Lin Lai, Chia-Wei Lee, Yi-Chung Lee, Yi-Chu Liao, Ueng-Cheng Yang, Tzu-Hao Cheng, Yijuang Chern, and Bing-Wen Soong, A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis. MOVEMENT DISORDERS 10.1002/mds.28896, 1-12 (2021-12) [JCR] [WOS]
- More Publications-

- POSTDOC -
Lee, Yan-Hua
Lee, Yan-Hua
Lin, Hsin-Chuan
Lin, Hsin-Chuan
Lin, Chien-Yu
Lin, Chien-Yu
Liu, Yu-Ju
Liu, Yu-Ju
Chang, Ching-Pang
Chang, Ching-Pang
Siew, Jian-Jing
Siew, Jian-Jing
Weng, Yu-Ting
Weng, Yu-Ting
- RESEARCH ASSOCIATES -
Lai, Hsing-Lin
Lai, Hsing-Lin
Chen, Huei-Mei
Chen, Huei-Mei
Lin, Todd
Lin, Todd
Wu, Ching-Wen
Wu, Ching-Wen
Lee, Willy
Lee, Willy
Pei-Rong, Chang
Pei-Rong, Chang
member
Yi-Ting, Lu
He, Chih Lin
He, Chih Lin
- STUDENTS -
NG, HIN FUNG JOSH
NG, HIN FUNG JOSH
Hsu, TengYang
Hsu, TengYang
Chan, Yee-Lam
Chan, Yee-Lam
Chang, Pi-Hsiang
Chang, Pi-Hsiang
Claire, Chuang
Claire, Chuang
Chang, Ya-Gin
Chang, Ya-Gin
- ALUMNI -
Lin, Yow-Sien
Lin, Yow-Sien
Chou, Szu-Yi
Chou, Szu-Yi
Wu, Yi-Chih
Wu, Yi-Chih
Lee, Chien-Fei
Lee, Chien-Fei
Ju, Tz-Chuen
Ju, Tz-Chuen
Hsiao, Han-Yun
Hsiao, Han-Yun
Sun, Chung-Nan
Sun, Chung-Nan
Wang, Jiz-Yuh
Wang, Jiz-Yuh
Chien, Chen-Li
Chien, Chen-Li
Chen, Yu-Chen
Chen, Yu-Chen
Lee, Li-Ming
Lee, Li-Ming
Wu, Tse Hsiang
Wu, Tse Hsiang
NGUYEN, THI NGOC ANH
NGUYEN, THI NGOC ANH
Wu, Yi-Ting
Wu, Yi-Ting
Huang, Haoning
Huang, Haoning
Lee, Chia-Chia
Lee, Chia-Chia
Jen, Wei-Ping
Jen, Wei-Ping
Wu, Yu-Shuo
Wu, Yu-Shuo
Chien, Ting
Chien, Ting
Lai, Jia-You
Lai, Jia-You
Lin, Meng-Syuan
Lin, Meng-Syuan
Hsu, Yi-Ting
Hsu, Yi-Ting
Tsai, Andy Po-Yi
Tsai, Andy Po-Yi